In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Society of Retina Specialists annual meeting, as well as Healio’s top headlines from the meeting.

Andrew G. Lee, MD, discusses when retina experts should refer patients to a neuro-ophthalmologist. 0:29

Sunir J. Garg, MD, FACS, FASRS, provides an overview of lessons learned from two complex surgical cases. 1:52

Sunir J. Garg, MD, FACS, FASRS, overviewed key findings from the Global Trends in Retina Survey. 5:16

Michael O’Rouke talks collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic diseases. 8:17

Jay S. Duker, MD, discusses EyePoint Pharmaceuticals’ second phase 3 trial of Duravyu in patients with wet age-related macular degeneration. 11:08

Read the full coverage here:

https://www.healio.com/news/ophthalmology/20250731/andrew-g-lee-shares-neuroophthalmology-advice-for-retina-specialists

https://www.healio.com/news/ophthalmology/20250731/sunir-garg-shares-solutions-to-complex-surgical-cases

https://www.healio.com/news/ophthalmology/20250730/revana-collaborates-with-boehringer-ingelheim-to-develop-extendedrelease-therapies

https://www.healio.com/news/ophthalmology/20250807/eyepoint-completes-enrollment-in-second-phase-3-trial-of-sustainedrelease-amd-therapy

https://www.healio.com/news/ophthalmology/20250811/survey-treatment-for-recalcitrant-diabetic-macular-edema-varies-between-us-europe

Long-term benefits seen with Gore-Tex sutures for scleral fixation of IOLs

Source: Acaba-Berrocal L, et al. Long-term outcomes of pars plana vitrectomy and polytetrafluoroethylene sutured scleral-fixated intraocular lenses. Presented at: American Society of Retina Specialists annual meeting; July 30-Aug. 2, 2025; Long Beach, California.

Study supports Iluvien as ‘long-acting option’ in diabetic macular edema

Source: Singer MA, et al. NEW DAY: Study design, study sites, patient enrollment: A study of intravitreal Iluvien (fluocinolone acetonide) implant as baseline therapy in patients with early diabetic macular edema (DME) (NEW DAY). Presented at: American Society of Retina Specialists annual meeting; July 30-Aug. 2, 2025; Long Beach, California.

Disclosures:

Duker reports being president and CEO of EyePoint Pharmaceuticals.

Garg reports no relevant financial disclosures.

Lee reports no relevant financial disclosures.

O’Rourke reports being CEO of Re-Vana Therapeutics.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

Chinmay Jani, MD, discusses findings highlighting how alcohol-related cancer mortality has risen sharply over the past few decades. :19

Rachel I. Vogel, PhD, provides and overview on factors contributing to the time burden cancer care places on patients. 3:02

Alexander D. Sherry, MD, discusses how improvements in OS or quality of life after phase 3 oncology trials are based on improvements in unvalidated alternative endpoints. 4:41

Lucas A. Mavromatis, ScB, discusses findings on how GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes. 7:20

Sonali M. Smith, MD, talks with Oncology Overdrive host Shikha Jain, MD, about presentations on lymphoma at this year’s ASCO meeting. 9:57

Read the full coverage here:

https://www.healio.com/news/hematology-oncology/20250531/study-reveals-shocking-rise-in-alcoholrelated-cancer-deaths

https://www.healio.com/news/hematology-oncology/20250603/time-burden-people-with-cancer-face-often-vastly-underestimated

https://www.healio.com/news/hematology-oncology/20250604/few-phase-3-oncology-trials-demonstrate-improvements-in-os-quality-of-life

https://www.healio.com/news/hematology-oncology/20250522/glp1-receptor-agonists-confer-modest-protection-against-obesityrelated-cancers

https://www.healio.com/news/hematology-oncology/podcasts/oncology-overdrive/episode-119

Exercise described as ‘novel, first-in-class’ colon cancer therapy

Source: Booth CM, et al. Abstract LBA3510. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

At-home intervention has potential to enhance cancer care delivery, outcomes

Source: Nipp RD, et al. Abstract 11003. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

Disclosures:

Jani reports no relevant financial disclosures.

Mavromatis reports no relevant financial disclosures.

Sherry reports honoraria from Sermo.

Smith reports no relevant financial disclosures.

Vogel reports a consulting/advisory role with Voluntis.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Academy of Neurology Annual Meeting.

Mary A. O'Neal, MD, FAAN, and Ratna K. Bhavaraju-Sanka, MD, FAAN, discuss their efforts to address the lack of access to neurological care by partnering with primary care. :34

Merit E. Cudkowicz, MD, MSc, FAAN, speaks with Healio about being honored The American Academy of Neurology’s Lifetime Achievement Award for her extensive work in ALS research. 2:50

Read the full coverage here:

https://www.healio.com/news/neurology/20250417/partners-in-crime-neurologists-collaborate-with-pcps-to-improve-brain-health

https://www.healio.com/news/neurology/20250407/merit-e-cudkowicz-md-msc-receives-lifetime-award-for-als-research-im-not-done-yet

ACCORD-2: AXS-05 delays relapse time to Alzheimer’s disease agitation

Source: Grossberg G, et al. Efficacy and safety of AXS-05 in Alzheimer's disease agitation: Results from ACCORD-2, a phase 3 randomized withdrawal double-blind placebo-controlled study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Risk for ARIA driven by patient genotype, presence of hemorrhage in early Alzheimer’s

Source: Biffi A, et al. ARIA insights from the donanemab trials: Amyloid-targeted therapy in early symptomatic Alzheimer’s disease. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Microplastics in oceans may increase disability risk among coastal populations

Source: Ganatra S, et al. Marine microplastics levels and the prevalence of neurologic disability. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Nightmares may increase risk for early death

Source: Otaiku A, et al. Distressing dreams and risk of premature mortality: A population-based multicohort study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Disclosures:

Bhavaraju-Sanka reports serving as a consultant for Amgen and Argenx.

Cudkowicz reports financial relationships with AB Science, AC Immune SA, Aclipse, Annals of Neurology, Biogen, Coya Therapeutics, Cytokinetics, Eli Lilly, Immunity Pharma, InFlectis, Locust Walk, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Pasithea Therapeutics, Pontifax, Praxis Precision Medicine, Transposon, QurAlis, Regeneron, VectorY. She also reports receiving publishing royalties from a publication relating to health care. Her institution(s) received support from ALS Finding a Cure, ALS ONE, Biohaven, Calico, Clene Nanomedicine, Denali, ITB, Johnson & Johnson, the National Institute of Neurological Disorders and Stroke, PharmAust, Prilenia, Seelos, UCB/RA and Woolsley.

O’Neal reports serving as a consultant and excerpt witness for Circo; being an employee of Best Doctors; and receiving publishing royalties from a health care-related publication.